Stability of Diluted Dexamethasone Sodium Phosphate Injection at Two Temperatures

1994 ◽  
Vol 28 (9) ◽  
pp. 1018-1019 ◽  
Author(s):  
Ralph A. Lugo ◽  
Milap C. Nahata
Keyword(s):  
Lung Disease ◽  
Bronchopulmonary Dysplasia ◽  
Chronic Lung Disease ◽  
Sodium Phosphate ◽  
Hplc Method ◽  
Dexamethasone Sodium Phosphate ◽  
Usp 4 ◽  
Two Temperatures ◽  
Phosphate Injection ◽  
The Stability

OBJECTIVE: Premature neonates with bronchopulmonary dysplasia frequently are treated with intravenous dexamethasone for their chronic lung disease. The injection volumes of the commercially available products often are too small to measure accurately. The objective of this study was to evaluate the stability over 28 days of dexamethasone sodium phosphate injection 4 mg/mL diluted with bacteriostatic NaCl 0.9% to 1 mg/mL. DESIGN: Ten vials of dexamethasone 1 mg/mL were prepared from dexamethasone sodium phosphate injection, USP 4 mg/mL and bacteriostatic NaCl 0.9% injection. Five vials were stored at 4 °C and five at 22 °C. Dexamethasone was measured on days 0, 1, 3, 7, 14, 21, and 28 by an accurate, reproducible, and stability-indicating HPLC method. Samples were also inspected visually for precipitation or discoloration on each study day. RESULTS: The samples retained at least 97.7 percent of the original concentration of dexamethasone sodium phosphate when stored at either 4 or 22 °C for 28 days. No discoloration or precipitation was observed. CONCLUSIONS: Dexamethasone sodium phosphate injection 1 mg/mL in bacteriostatic NaCl 0.9% was stable for 28 days at 4 and 22 °C.

Bronchopulmonary Dysplasia and Care Techniques

PEDIATRICS ◽  
1987 ◽  
Vol 80 (1) ◽  
pp. 121-122
Author(s):  
ALISTAIR G. S. PHILIP ◽  
DALE L. KESSLER
Keyword(s):  
Lung Disease ◽  
Bronchopulmonary Dysplasia ◽  
Study Design ◽  
Chronic Lung Disease ◽  
Oxygen Requirement ◽  
End Point ◽  
Definition Of

To the Editor.— Although the paper by Avery et al1 is both interesting and provocative, readers should be cautioned about the inherent limitations of data generated by a retrospective, multicentered study design. First, the definition of chronic lung disease leaves much to be desired. The diagnosis was "arbitrarily defined" as an oxygen requirement greater than room air at 28 days of age. Evaluation of the need for oxygen at 3 months is a much more clinically relevant end point, but the numbers in this category were too small to evaluate adequately.

The BPD Problem

PEDIATRICS ◽  
1991 ◽  
Vol 88 (1) ◽  
pp. 189-190
Author(s):  
T. A. MERRITT ◽  
W. NORTHWAY ◽  
B. R. BOYNTON ◽  
D. K. EDWARDS ◽  
M. HALLMAN ◽  
...  
Keyword(s):  
Lung Disease ◽  
Bronchopulmonary Dysplasia ◽  
Chronic Lung Disease ◽  
Supplemental Oxygen ◽  
Statistical Analyses

To the Editor.— Sinkin and co-workers1 undertook the laudable goal of attempting to predict the risk of "bronchopulmonary dysplasia" (defined solely as a requirement for supplemental oxygen at 28 days) to select better infants who might benefit from interventions to reduce the frequency of this chronic lung disease. Other investigators have defined risk of bronchopulmonary dysplasia (BPD) in the first days to weeks of life using similar statistical analyses,2,3 cytopathology,4 detection of elevated proteases in airway secretions,5-7 measurement of airways mechanics,8,9 and clinical and radiographic scores.10,11

Bronchopulmonary Dysplasia and Chronic Lung Disease

2015 ◽  
Vol 42 (4) ◽  
pp. 889-910 ◽  
Author(s):  
Maria Pierro ◽  
Elena Ciarmoli ◽  
Bernard Thébaud
Keyword(s):  
Lung Disease ◽  
Bronchopulmonary Dysplasia ◽  
Chronic Lung Disease

scholarly journals Using Cell-Based Strategies to Break the Link between Bronchopulmonary Dysplasia and the Development of Chronic Lung Disease in Later Life

2013 ◽  
Vol 2013 ◽  
pp. 1-10 ◽  
Author(s):  
Megan O'Reilly ◽  
Bernard Thébaud
Keyword(s):  
Lung Disease ◽  
Bronchopulmonary Dysplasia ◽  
Chronic Lung Disease ◽  
Perinatal Care ◽  
Specific Treatment ◽  
Extreme Prematurity ◽  
Very Preterm ◽  
Recent Advances ◽  
Increased Risk ◽  
Lung Dysfunction

Bronchopulmonary dysplasia (BPD) is the chronic lung disease of prematurity that affects very preterm infants. Although advances in perinatal care have changed the course of lung injury and enabled the survival of infants born as early as 23-24 weeks of gestation, BPD still remains a common complication of extreme prematurity, and there is no specific treatment for it. Furthermore, children, adolescents, and adults who were born very preterm and developed BPD have an increased risk of persistent lung dysfunction, including early-onset emphysema. Therefore, it is possible that early-life pulmonary insults, such as extreme prematurity and BPD, may increase the risk of COPD later in life, especially if exposed to secondary challenges such as respiratory infections and/or smoking. Recent advances in our understanding of stem/progenitor cells and their potential to repair damaged organs offer the possibility of cell-based treatments for neonatal and adult lung injuries. This paper summarizes the long-term pulmonary outcomes of preterm birth and BPD and discusses the recent advances of cell-based therapies for lung diseases, with a particular focus on BPD and COPD.

Sign in / Sign up

Export Citation Format

Share Document